- Home
- NBB vs PACB Comparison
NBB vs PACB Comparison
Compare NBB & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBB | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.7M | 459.0M |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NBB | PACB |
|---|---|---|
| Price | $15.56 | $1.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.10 |
| AVG Volume (30 Days) | 54.1K | ★ 5.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $14.52 | $0.85 |
| 52 Week High | $16.62 | $2.73 |
Technical Indicators
Market Signals| Indicator | NBB | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 35.78 |
| Support Level | $15.29 | $1.18 |
| Resistance Level | $16.37 | $1.37 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 13.50 | 19.09 |
Price Performance
Historical ComparisonAbout NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.